The Prescription Drug Affordability Board (PDAB) has selected 6 drugs they propose to subject to a cost review process. If members wish to submit comments on any or all the choices, please send them to comments.pdab@maryland.gov with the subject line: Board Selected Drugs (Drug Name) by July 22. For more information on the PDAB or on the comment process, see the PDAB’s Board Selected Drugs Page.
Also in Maryland, Medicaid Fee-For-Service released Advisory #263 in reference to the Generic vs. Brand Status on Medicaid’s Preferred Drug List (PDL) effective July 1, 2024.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.